Clinical Trials: An Evaluation of the Efficacy and Safety of AL-46383A Ophthalmic Solution for the Treatment of Adenoviral Conjunctivitis

Article

This clinical trial will determine if AL-46383A ophthalmic solution is an effective treatment for adenoviral conjunctivitis.

Study Type: Interventional

Age/Gender Requirements: 6 years+ (male/female)

Sponsor: Alcon Research

Purpose: To determine the safety and efficacy of AL-46383A Ophthalmic Solution in the treatment of adenoviral conjunctivitis.

Click here to access this third-party resource.

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
A panel of 5 experts on iron deficiency anemia
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Phase 2 Data Shows KP1077 Meaningfully Improves Idiopathic Hypersomnia Symptoms
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Related Content
Male Sex, Younger Age Linked to Sickle Cell Retinopathy Progression | Image Credit: LinkedIn

Male Sex, Younger Age Linked to Sickle Cell Retinopathy Progression

Connor Iapoce
July 25th 2024
Article
Health Consequences of Climate Change with Janelle Bludorn, PA-C, MS

Health Consequences of Climate Change with Janelle Bludorn, PA-C, MS

Kevin Kunzmann
July 22nd 2024
Podcast
Physical Activity Linked to Reducing Depression Symptoms, Mediated by Pain

Physical Activity Linked to Reducing Depression Symptoms, Mediated by Pain

Chelsie Derman
July 25th 2024
Article
Innovations in GERD: What Vonoprazan (Voquezna) May Offer Over PPIs, with Adelina Hung, MD

Innovations in GERD: What Vonoprazan (Voquezna) May Offer Over PPIs, with Adelina Hung, MD

Abigail Brooks, MA
July 18th 2024
Podcast
Arthritis Disease Severity Peaks in Spring and Fall, According to PROs

Arthritis Disease Severity Peaks in Spring and Fall, According to PROs

Lana Pine
July 25th 2024
Article
Adi Mor, PhD | Credit: Chemomab

SPRING: CM-101, A CCL24-Neutralizing Antibody, Impresses in Phase 2 PSC Trial

Abigail Brooks, MA
July 25th 2024
Article
© 2024 MJH Life Sciences

All rights reserved.